Global Markets Direct’s, ‘Cellectis S.A. - Product Pipeline Review - 2016’, provides an overview of the Cellectis S.A.’s pharmaceutical research and development focus.
The report provides comprehensive information on the therapeutics under development by Cellectis S.A., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
- The report provides a snapshot of the pipeline therapeutic landscape of Cellectis S.A. - The report provides overview of Cellectis S.A. including its business description, key facts, and locations and subsidiaries - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report assesses Cellectis S.A.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report features Cellectis S.A.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
Reasons to buy
- Evaluate Cellectis S.A.’s strategic position with total access to detailed information on its product pipeline - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Cellectis S.A. - Identify potential new clients or partners in the target demographic - Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Cellectis S.A.’s pipeline depth and focus of pipeline therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Our reports have been used by over 10K customers, including:
Rhabdomyosarcoma Global Clinical Trials Review, H1, 2020 Summary This clinical trial report, “Rhabdomyosarcoma Global Clinical Trials Review, H1, 2020" provides an overview of Rhabdomyosarcoma Clinical trials scenario.This report provides top line data relating to the clinical trials on Rhabdomyosarcoma...
Toll Like Receptor 4 - Pipeline Review, H1 2020 Summary According to the recently published report ’Toll Like Receptor 4 – Pipeline Review, H1 2020’; Toll Like Receptor 4 (hToll or CD284 or TLR4) pipeline Target constitutes close to 44 molecules. Out of which approximately 35 molecules are developed...
Age Related Macular Degeneration - Pipeline Review, H1 2020 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Age Related Macular Degeneration - Pipeline Review, H1 2020, provides an overview of the Age Related Macular Degeneration (Ophthalmology) pipeline landscape. Age...
Respiratory Syncytial Virus Attachment Glycoprotein - Pipeline Review, H1 2020 Summary Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) – Respiratory syncytial virus G protein is a protein produced by respiratory syncytial virus. It attaches the virion to the host cell membrane by...